Search Courses

Course Catalog

Miscellaneous Courses
  • Course Code
    AVIR2021-1
    Available Until
    3/30/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    9:45a Presidential WelcomeRennie Mohabir, MBA, RT(R) (no CE)
    10:00a Evolution not Revolution - Indispensable CARE - Dr Janice Newsome, Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access - Dr Mark Lessne
    11:40a Covid-19 - Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization - Dr Kavi Devulapalli
    2:00p PAD Inflow - Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE)
    2:50p PE Interventions - Dr Charles Ritchie
    3:45p Combating Burnout - Dr Agnes Solberg
    4:20p Radiation Safety - Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-10
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-11
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-12
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-13
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke - Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-14
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-15
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-16
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-17
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-18
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-19
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-2
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-20
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-21
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-22
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-23
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-24
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-25
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-26
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-27
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-3
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-4
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE)
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-5
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-6
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-7
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-8
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-9
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke - Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

Miscellaneous Courses
  • Course Code
    AVIR-DJR46
    Available Until
    6/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To assess biopsy technique, technical success rate, and diagnostic yield of image-guided percutaneous biopsy of omental and
    mesenteric lesions.
    Materials and Methods: This retrospective study included 186 patients (89 men, 97 women; mean [SD] age, 63 [13.8] y) who
    underwent percutaneous image-guided biopsy of omentum and mesentery between March 2007 and August 2015. Biopsies were
    performed with computed tomography (CT) (n 1⁄4 172) or ultrasound (US) (n 1⁄4 14) guidance using coaxial technique yielding core and
    fine-needle aspiration (FNA) specimens. Biopsy results were classified as diagnostic (neoplastic or nonneoplastic) or nondiagnostic
    based on histopathology and cytology. Technical success rate and diagnostic yield of omental and mesenteric lesions were calculated.
    Results: There were 186 image-guided percutaneous biopsies of omental (n 1⁄4 95) and mesenteric (n 1⁄4 91) lesions performed. Technical
    success rate was 99.5% for all biopsies, 100% for omental biopsies, and 98.9% for mesenteric biopsies. Overall sensitivity was 95.5%,
    specificity was 100%, negative predictive value was 78.3%, and positive predictive value was 100%, which was comparable for omental
    and mesenteric biopsies. Core biopsies had higher diagnostic yields compared with FNA: 98.4% versus 84% overall, 99% versus 88% for
    omental biopsies, and 97.7% versus 80% for mesenteric biopsies. Spearman rank correlation showed no correlation between lesion size
    and diagnostic yield (P 1⁄4 .14) and lesion depth and diagnostic yield (P 1⁄4 .29) for both groups. There were 5 complications.
    Conclusions: Image-guided percutaneous omental and mesenteric biopsies have high technical success rates and diagnostic yield
    regardless of lesion size or depth from the skin for both omental and mesenteric specimens.

  • Course Code
    AVIR-DJR49
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To evaluate the efficacy and safety of embolization of hyperemic synovial tissue for the treatment of knee pain secondary to
    osteoarthritis (OA).
    Materials and Methods: Twenty patients with radiographic knee OA and moderate-to-severe pain refractory to conservative therapy
    were enrolled in a prospective, 2-site pilot study. Genicular artery embolization (GAE) was performed with 75- or 100-μm spherical
    particles. Patients were assessed with magnetic resonance imaging at baseline and at 1 month and with the Visual Analogue Scale (VAS)
    and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and at 1, 3, and 6 months. Adverse
    events were recorded at all timepoints.
    Results: Embolization of at least 1 genicular artery was achieved in 20/20 (100%) patients. Mean VAS improved from 76 mm ± 14 at
    baseline to 29 mm ± 27 at 6-month follow-up (P <.01). Mean WOMAC score improved from 61 ± 12 at baseline to 29 ± 27 at 6-month
    follow-up (P < .01). Self-limiting skin discoloration occurred in 13/20 (65%) patients. Two of 20 (10%) patients developed plantar
    sensory paresthesia that resolved within 14 days.

    Conclusions: GAE to treat knee pain secondary to OA can be performed safely and demonstrates potential efficacy. Further ran-
    domized comparative studies are needed to determine true treatment effect versus placebo effect.

  • Course Code
    AVIR-DJR50
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Structured Education: 

    RA - 2017 Patient Care - Patient Interactions and Management

    0.50

    RA - 2018 Patient Care - Patient Management

    0.50

    VI - 2016 Patient Care - Patient Interactions and Management

    0.50

    VI - 2017 Patient Care - Patient Interactions and Management

    0.50

    RA - 2017 Procedures - Musculoskeletal and Endocrine Sections

    0.50

    RA - 2018 Procedures - Musculoskeletal and Endocrine Sections

    0.50

    VI - 2016 Procedures - Abdominal Angiography and Intervention, GU and GI Nonvascular Procedures

    0.50

    VI - 2017 Procedures - Vascular Diagnostic Procedures

    0.50

  • Course Code
    AVIR-DJR51
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To establish a nomogram for predicting the occurrence of early biliary infection (EBI) after percutaneous transhepatic biliary
    stent (PTBS) placement in malignant biliary obstruction (MBO).
    Materials and Methods: In this multicenter study, patients treated with PTBS for MBO were allocated to a training cohort or a
    validation cohort. The independent risk factors for EBI selected by multivariate analyses in the training cohort were used to develop a
    predictive nomogram. An artificial neural network was applied to assess the importance of these factors in predicting EBI. The predictive
    accuracy of this nomogram was determined by concordance index (c-index) and a calibration plot, both internally and externally.
    Results: A total of 243 patients (training cohort: n 1⁄4 182; validation cohort: n 1⁄4 61) were included in this study. The independent risk
    factors were length of obstruction (odds ratio [OR], 1.061; 95% confidence interval [CI], 1.013–1.111; P 1⁄4 .012), diabetes (OR, 5.070;
    95% CI, 1.917–13.412; P 1⁄4 .001), location of obstruction (OR, 2.283; 95% CI, 1.012–5.149; P 1⁄4 .047), and previous surgical or
    endoscopic intervention (OR, 3.968; 95% CI, 1.709–9.217; P 1⁄4 .001), which were selected into the nomogram. The c-index values
    showed good predictive performance in the training and validation cohorts (0.792 and 0.802, respectively). The optimum cutoff value of
    risk was 0.25.
    Conclusions: The nomogram can facilitate the early and accurate prediction of EBI in patients with MBO who underwent PTBS.
    Patients with high risk (> 0.25) should be administered more effective prophylactic antibiotics and undergo closer monitoring.

    NMT - 2017 Procedures

    Gastrointestinal and Genitourinary Procedures

    0.50

    PTH - 2019 Procedures

    Treatment Sites

    0.25

    RA - 2017 Procedures

    Abdominal Section

    1.00

    RA - 2018 Procedures

    Abdominal Section

    1.00

    SON - 2016 Procedures

    Abdominal and Transplant Vasculature

    0.50

    SON - 2019 Procedures

    Abdomen

    0.50

    THR - 2017 Procedures

    Treatment Sites and Tumors

    0.25

    VI - 2016 Procedures

    Abdominal Angiography and Intervention, GU and GI Nonvascular Procedures

    1.00

    VI - 2017 Procedures

    Nonvascular Procedures

  • Course Code
    AVIR-DJR52
    Available Until
    9/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00
  • Course Code
    AVIR-DJR53
    Available Until
    9/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To examine the safety of therapeutic-dose anticoagulation during catheter-directed thrombolysis (CDT) for acute pulmonary
    embolism (PE).
    Materials and Methods: A retrospective review of 156 consecutive cases (age, 56.6 ± 15.4 years; 85 males) of CDT with alteplase
    for acute PE (symptoms, <14 days) between 2009 and 2019 was performed. All patients received full-dose anticoagulation before,
    during, and after thrombolysis with low-molecular-weight heparin (LMWH) (n 1⁄4 45) or unfractionated heparin (n 1⁄4 111) infusion.
    Massive PE was diagnosed in 21 of 156 patients at presentation; submassive PE was diagnosed in 135 of 156 patients at presentation.
    The Simplified Pulmonary Embolism Severity Index was 1 in 69 of 156 patients.
    Results: There were 4 mild (2.6%), 3 moderate (1.9%), and 3 severe (1.9%) hemorrhagic complications (Global Use of Strategies to
    Open Occluded Arteries), 1 of which (0.6%) was intracranial. No significant differences in hemorrhagic complication rates (P 1⁄4 .3,
    P 1⁄4 1.0, and P 1⁄4 .6, respectively) or general complication rates (Society of Interventional Radiology [SIR] minor, P 1⁄4 .2; SIR major,
    P 1⁄4.7) were noted between the LMWH and heparin groups. Mean pulmonary arterial pressure for the entire cohort improved from 28.9
    ± 7.6 mmHg to 20.4 ± 6.5 mmHg (P < .001), whereas the Miller score improved from 19.3 ± 4.6 to 7.3 ± 3.9 (P < .001). The average
    infusion duration was 26 ± 11.9 hours over 2.3 ± 0.6 total visits to the angiography lab, during which a mean of 27.85 ± 14.2 mg of
    tissue plasminogen activator were infused.
    Conclusions: Therapeutic anticoagulation during CDT for PE appears to be safe. The current study did not find a significant difference
    between LMWH and heparin infusion with respect to hemorrhagic and general complication rates.

  • Course Code
    AVIR-DJR54
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Obesity is a public health epidemic in the United States that results in significant morbidity, mortality, and cost to the health
    care system. Despite advancements in therapeutic options for patients receiving bariatric procedures, the number of overweight
    and obese individuals continues to increase. Therefore, complementary or alternative treatments to lifestyle changes and surgery
    are urgently needed. Embolization of the left gastric artery, or bariatric arterial embolization (BAE), has been shown to
    modulate body weight in animal models and early clinical studies. If successful, BAE represents a potential minimally invasive
    approach offered by interventional radiologists to treat obesity. The purpose of the present review is to introduce the
    interventional radiologist to BAE by presenting its physiologic and anatomic bases, reviewing the preclinical and clinical data,
    and discussing current and future investigations.

  • Course Code
    AVIR-DJR55
    Available Until
    6/1/2023
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To compare the utility of low-dose versus standard cone-beam computed tomography (CT) angiography protocols in
    identifying nontarget embolization (NTE) during prostatic artery embolization (PAE).
    Materials and Methods: A prospective, single-center, Phase-1 study (NCT02592473) was conducted for lower urinary tract
    symptoms in benign prostatic hyperplasia. Prostate volume, international prostate symptom score (IPSS), quality of life score (QoL),
    International Index of Erectile Function (IIEF), peak flow rate, UCLA Prostate Cancer Index (UCLA-PCI), and postvoid residual were
    recorded at baseline and 1, 3, 6, 12, and 24-months after PAE. Six-second (standard protocol, n 1⁄4 29) or 5-second (low-dose protocol
    n 1⁄4 45) rotations were made. Images were selected and matched in pairs by areas of NTE and compared by readers using a binomial
    generalized estimating equation model. Procedural outcomes were analyzed using a linear mixed model.
    Results: Seventy-four cone-beam CT angiographies were performed in 21 patients. IPSS and QoL scores significantly improved (P
    <.05). There was no change in UCLA-PCI or IIEF scores. Dose area product of the low- and standard-dose protocol were 37,340.82
    mGy$cm2 ± 104.66 and 62,645.66 mGy$cm2 ± 12,711.48, respectively, representing a dose reduction of 40.4%. A total of 120

    comparisons showed no preference between the 2 protocols (P 1⁄4.24). Observers identified 76 and 69 instances of NTE in the standard-
    and low-dose protocols, respectively (P 1⁄4.125).

    Conclusions: Low-dose cone-beam CT angiography achieved equivalent clinical utility in identifying NTE during PAE, with the
    advantage of a lower radiation dose.

  • Course Code
    AVIR-DJR56
    Available Until
    9/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To compare outcomes after endovascular treatment (EVT) for acute ischemic stroke with and without the use of a balloon
    guide catheter (BGC) in clinical practice.
    Materials and Methods: Data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic
    Stroke in The Netherlands (MR CLEAN) Registry were used, in which all patients who underwent EVT for anterior-circulation stroke in
    The Netherlands between 2014 and 2016 were enrolled. Primary outcome was modified Rankin scale (mRS) score at 90 days. Secondary
    outcomes included reperfusion grade (extended Thrombolysis In Cerebral Infarction [eTICI] score) and National Institutes of Health
    Stroke Scale (NIHSS) score 24–48 hours after intervention. The association between the use of a BGC and outcomes was estimated with
    logistic regression adjusted for age, sex, prestroke mRS score, NIHSS score, collateral grade, and time from onset to EVT.
    Results: A total of 887 patients were included. Thrombectomy was performed with the use of a BGC in 528 patients (60%) and
    without in 359 patients (40%). There was no significant association between use of a BGC and a shift on the mRS toward better outcome
    (adjusted common odds ratio, 1.17; 95% confidence interval [CI], 0.91–1.52). Use of a BGC was associated with higher eTICI score
    (adjusted common OR, 1.33; 95% CI, 1.04–1.70) and improvement of  4 points on the NIHSS (adjusted OR, 1.40; 95% CI, 1.04–
    1.88).
    Conclusions: In clinical practice, use of a BGC was associated with higher reperfusion grade and early improvement of neurologic
    deficits, but had no positive effect on long-term functional outcome.

  • Course Code
    AVIR-DJR57
    Available Until
    9/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Augmented and mixed reality are emerging interactive and display technologies. These technologies are able to merge virtual objects, in
    either 2 or 3 dimensions, with the real world. Image guidance is the cornerstone of interventional radiology. With augmented or mixed
    reality, medical imaging can be more readily accessible or displayed in actual 3-dimensional space during procedures to enhance
    guidance, at times when this information is most needed. In this review, the current state of these technologies is addressed followed by a
    fundamental overview of their inner workings and challenges with 3-dimensional visualization. Finally, current and potential future
    applications in interventional radiology are highlighted.

  • Course Code
    AVIR-DJR58
    Available Until
    11/1/2023
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To compare patients treated with large-volume paracentesis (LVP), transjugular intrahepatic portosystemic shunt (TIPS), and
    peritoneovenous shunt (PVS) for ascites.
    Materials and Methods: A retrospective study of 192 patients treated with LVP (94), TIPS (75), or PVS (23) was performed.
    Records were reviewed for patient characteristics and outcomes. The patients’ age differed (LVP, 59.5 years; TIPS, 58.8 years; and PVS,
    65.6 years; P 1⁄4 .003). Nonalcoholic steatohepatitis was the most common etiology in the PVS cohort (11/23, 47%), and hepatitis C in
    the TIPS (27/75, 36%), and LVP cohorts (43/94, 46%) (P 1⁄4.032). The model for end-stage liver disease score was significantly different
    (LVP, 14; TIPS, 13; and PVS, 8; P 1⁄4 .035). Hepatocellular carcinoma was higher in the PVS cohort (6/23 patients, 25%) than in the
    TIPS (4/75, 5%), and LVP (12/94, 12%) cohorts (P 1⁄4 .03).
    Results: Emergency department visits and hospital readmissions were the highest in the LVP cohort (40%, 2 readmissions, P <
    .001). Patients required fewer LVPs after TIPS (1.5 to 0.14, P < .001) or PVS (2.1 to 0.5, P 1⁄4 .019). In an unadjusted Cox model,
    patients in the TIPS cohort were found to have a 58% reduction in the risk of death compared with patients in the LVP cohort (P 1⁄4.003).
    Transplant-free survival (PVS, 44 days; TIPS, 155 days; and LVP, 213 days) differed (log rank 1⁄4 0.001).
    Conclusions: The survival in the PVS and TIPS cohorts was similar, with less healthcare utilization than the LVP cohort. PVS is a
    satisfactory alternative to LVP.

  • Course Code
    AVIR-DJR59
    Available Until
    12/1/2023
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: This study sought to define thromboembolic risk and mortality in patients with heparin-induced thrombocytopenia (HIT)
    undergoing inferior vena cava filter (IVCF) placement, in light of the American Society of Hematology’s 2018 guidelines against routine
    use of IVCFs in this population.
    Methods: A total of 26 patients with HIT who received IVCFs were retrospectively reviewed, and the outcomes of this group were
    compared with those of 4,707 controls with either HIT or IVCFs alone and with reported outcomes in prior studies.
    Results: The patient group demonstrated 6- and 12-month mortality rates of 26.9% and 30.8%, respectively, which did not differ

    significantly from those of the control groups and were in line with published mortality rates in the literature. The measured throm-
    boembolic risk of 19.2% in the patient group was also within the range of published rates for patients with HIT or IVCF alone.

    Conclusions: IVCF placement did not significantly increase the risk of thromboembolism or death in patients with HIT and may be a
    viable option in the subset of these patients who are not candidates for anticoagulation.

  • Course Code
    AVIR-DJR60
    Available Until
    1/9/2023
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    An abnormally invasive placenta is an increasing and potentially life-threatening pregnancy complication. The case presented herein is a
    heterotopic dichorial pregnancy with implantation of 1 placenta within the isthmocervical area, which caused vaginal bleeding during
    the 20th week of pregnancy, requiring a blood transfusion. To stop the bleeding, a bilateral embolization of the cervical branches of the
    uterine arteries was performed. The embolization was well tolerated and resulted in the abrupt and lasting cessation of bleeding for more
    than 10 weeks, resulting in the live birth of 1 child.

  • Course Code
    AVIR-DJR61
    Available Until
    1/8/2023
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To analyze the impact of physician-specific equipment preference on cost variation for procedures typically performed by
    interventional radiologists at a tertiary care academic hospital.
    Materials and Methods: From October 2017 to October 2019, data on all expendable items used by 9 interventional radiologists for
    11 common interventional radiology procedure categories were compiled from the hospital analytics system. This search yielded a final
    dataset of 44,654 items used in 2,121 procedures of 11 different categories. The mean cost per case for each physician as well as the
    mean, standard deviation, and coefficient of variation (CV) of the mean cost per case across physicians were calculated. The proportion
    of spending by item type was compared across physicians for 2 high-variation, high-volume procedures. The relationship between the
    mean cost per case and case volume was examined using linear regression.
    Results: There was a high variability within each procedure, with the highest and the lowest CV for radioembolization administration
    (56.6%) and transjugular liver biopsy (4.9%), respectively. Variation in transarterial chemoembolization cost was mainly driven by
    microcatheters/microwires, while for nephrostomy, the main drivers were catheters/wires and access sets. Mean spending by physician
    was not significantly correlated with case volume (P 1⁄4.584).
    Conclusions: Physicians vary in their item selection even for standard procedures. While the financial impact of these differences vary
    across procedures, these findings suggest that standardization may offer an opportunity for cost savings.